Evonile Pharma Ltd Business Overview - SOIC x StockScans Report

as of Jul 2026

Novartis India is fundamentally a pharmaceutical trading house - it buys finished medicines from its Swiss parent and sells them to Indian hospitals and distributors, owning no factories of its own. Incorporated in 1947 and operating in India for over 75 years, the company was a subsidiary of Novartis AG, Switzerland until February 2026, when the parent agreed to sell its entire 70.68% stake to the ChrysCapital private equity group, triggering a change of control and a proposed name change. Its recurring approach has been to differentiate branded medicines in a market dominated by cheap generics through scientific engagement with doctors - using targeted digital campaigns, continuing medical education, and partnerships with medical associations - while progressively shifting to an asset-light model that outsources distribution of its largest brands to Dr. Reddy's Laboratories.

Business segments

A single pharmaceutical trading engine, split into two go-to-market streams - a direct scientific-marketing arm for specialist transplant and neurology medicines, and an outsourced distribution arm for mass-market pain and calcium brands.

1. Specialist medicines: branded drugs sold on scientific trust

The company imports high-value immunosuppressants and neurology drugs from its Swiss parent and sells them to Indian hospitals and distributors, competing against cheap generics by building deep relationships with transplant surgeons and neurologists.

2. Established medicines: mass-market brands distributed by a partner

The Voveran pain-relief range, the Calcium range, and Methergine are sold through an exclusive distribution deal with Dr. Reddy's Laboratories, trading direct control for wider reach.

Group structure and partners

The company is being sold by its Swiss parent to a private equity group with an existing Indian pharma portfolio, in a transaction that will change its name, its board, and potentially its commercial agreements.